Dr. Luke on the FDA Approval of Adjuvant Nivolumab in Melanoma | OncLive

Dr. Luke on the FDA Approval of Adjuvant Nivolumab in Melanoma

December 21, 2017

Jason J. Luke, MD, assistant professor of medicine, University of Chicago Medicine, discusses the FDA approval of nivolumab (Opdivo) to treat patients with melanoma who are at high risk of disease recurrence following complete surgical resection.

Jason J. Luke, MD, assistant professor of medicine, University of Chicago Medicine, discusses the FDA approval of nivolumab (Opdivo) to treat patients with melanoma who are at high risk of disease recurrence following complete surgical resection.


x